Topline data from the phase 3 E-BEOND and C-BEOND trials show a significant reduction in monthly migraine days at 24 weeks, demonstrating efficacy across the full migraine spectrum.

In a new update issued today (July 15), the Medicines and Healthcare products Regulatory Agency (MHRA) confirmed it is stepping up its safety warnings for all products containing botulinum toxin type ...

CKD Bio marked the first anniversary of its proprietary botulinum toxin Tmbus Inj. by hosting a symposium to share clinical ...

Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) ...

BETWEEN social media, work calls and selfies, these days we’re constantly looking at ourselves on screen. Meanwhile, celebs ...

Daewoong Pharmaceutical said Monday that cumulative sales of its proprietary botulinum toxin product Nabota surpassed 1 ...

The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

World Plastic Surgery Day is observed every year on July 15. The day highlights the important role of plastic surgeons in ...

Daewoong Pharma's in-house botulinum toxin product Nabota has surpassed 1 trillion won ($665 million) in cumulative sales, ...

Whether a person lives in Hawaii, the Mojave Desert or in Oklahoma, skin care is important, and proper care involves sun protection. Aracelly Walden is an esthetician who travels back and forth to ...

In the fifth instalment of School of Beauty, A/Prof Tim Papadopoulos reflects on ageing, Stoic philosophy and why the goal of ...

The Centers for Medicare and Medicaid Services (CMS) on July 7, 2026, issued a proposed rule (CMS-1850-P) for calendar year ...